

# VT PATENTES

# BIOTECNOLOGÍA SANITARIA

Degeneración macular  
Diabetes  
Sistema nervioso  
Sistema inmune

# 38



**Vigilancia  
Tecnológica**  
4º trimestre 2022

NIPO: 116-19-008-3

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el

mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular. A través del número de publicación de cada patente, un enlace permite consultar el documento completo e incluso poder disponer de una traducción de la descripción realizada con la herramienta Patent translate.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente [formulario de suscripción](#).

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


## Contenido




**DEGENERACIÓN  
MACULAR**



**DIABETES**



**SISTEMA NERVIOSO**



**SISTEMA INMUNE**

# Degeneración Macular

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022251484</a>	APELLIS PHARMACEUTICALS INC [US]	Treatment of complement-mediated disorders
<a href="#">WO2022250389</a>	IUCF HYU [KR]	Novel <i>Dunariella salina</i> and uses thereof
<a href="#">WO2022247917</a>	SHANGHAI REGENEAL THERAPIE CO LTD [CN]	Recombinant adeno-associated virus having variant capsid, and application thereof
<a href="#">WO2022235983</a>	KYPHA INC [US]	Target measurement
<a href="#">WO2022232178</a>	4D MOLECULAR THERAPEUTICS INC [US]	Compositions and methods for treatment of ocular disease associated with angiogenesis
<a href="#">WO2022232249</a>	UNIV COLUMBIA [US]	Methods and compositions to regulate cholesterol efflux to prevent, treat, or cure macular degeneration
<a href="#">WO2022217110</a>	AVIRMAX INC [US]	Compositions and methods for ocular transgene expression
<a href="#">WO2022206838</a>	HANGZHOU JIAYIN BIOTECH LTD [CN]; HANGZHOU EXEGENESIS BIO LTD [CN]	Fusion molecules targeting VEGF and angiopoietin and uses thereof
<a href="#">WO2022192755</a>	MARVELBIOME INC [US]	Methods and uses of microbiome compositions, components, or metabolites for treating eye disorders
<a href="#">WO2022201084</a>	NOVARTIS AG [CH]	Methods for treating ocular diseases
<a href="#">WO2022189344</a>	UNIV GENT [BE]	Treatment of eye diseases with fructosyl-amino acid oxidase
<a href="#">WO2022256557</a>	DYNO THERAPEUTICS INC [US]	Capsid variants and methods of using the same
<a href="#">WO2022256331</a>	SCHEPENS EYE RES INST [US]	Methods for treating neurodegeneration targeting IGF1/IGF1R

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022198108</a>	AFFILOGIC [FR]; APELLIS PHARMACEUTICALS INC [US]	Polypeptides for complement inhibition
<a href="#">WO2022199603</a>	NANJING GENSCRIPT BIOTECH CO LTD [CN]	Antibody fusion proteins and uses thereof

# Diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022257979</a>	SCRIPPS RESEARCH INST [US]; SHEN WEIJUN [CN]	Long-acting dual GIP/GLP-1 peptide conjugates and methods of use
<a href="#">WO2022247917</a>	SHANGHAI REGENEAL THERAPIE CO LTD [CN]	Recombinant adeno-associated virus having variant capsid, and application thereof
<a href="#">WO2022245065</a>	ICURE BNP CO LTD [KR]	Complex including cell-permeable peptide and glucagon-like peptide-1 receptor agonist
<a href="#">WO2022244854</a>	NATIONAL UNIV CORPORATION UNIV OF TOYAMA [JP]	Anti-CD206 antibody and use thereof
<a href="#">WO2022240797</a>	UNIV TOLEDO [US]	Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
<a href="#">WO2022226054</a>	CUE BIOPHARMA INC [US]	Antigen presenting polypeptide complexes bearing TGF-beta and methods of use thereof
<a href="#">WO2022226091</a>	UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]	Smad2 inhibition in beta cells for type 2 diabetes therapy
<a href="#">WO2022226058</a>	CUE BIOPHARMA INC [US]	Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
<a href="#">WO2022226031</a>	RAGHUNATHAN VIJAY KRISHNA [US]; MURPHY CHRISTOPHER J [US]; ABBOTT NICHOLAS L [US]	Growth factor conjugates
<a href="#">WO2022226069</a>	CUE BIOPHARMA INC [US]	MHC class II T-cell modulatory polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
<a href="#">WO2022217110</a>	AVIRMAX INC [US]	Compositions and methods for ocular transgene expression
<a href="#">WO2022213353</a>	UNIV BEIJING [CN]	siRNA, medical compositions, and methods for treating diabetes using the same
<a href="#">WO2022212393</a>	UNIV CALIFORNIA [US]	Transplanted cell protection via modified Fc receptors
<a href="#">WO2022206895</a>	UNIV HONG KONG CHINESE [CN]	Use of microbiome for assessment and treatment of obesity and type 2 diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022206857</a>	GMAX BIOPHARM LLC [CN]	Antibody capable of specifically binding to human endothelin receptor, and use thereof in treatment of diabetic nephropathy and chronic nephropathy
<a href="#">WO2022203533</a>	VOLOBUEV VLADIMIR VALEREVICH [RU]	Method for assessing predisposition to different forms of type II diabetes mellitus
<a href="#">WO2022201832</a>	NISSHIN OILLIO GROUP LTD [JP]	Screening method for GLP-1 secretion control agent, GLP-1 secretion control agent, composition for preventing or ameliorating diabetes, obesity, postprandial hyperglycemia, neurodegenerative disease, hypoglycemia, adiposity, or nesidioblastosis, method for promoting secretion of GLP-1 in GPR84-expressing cells, method for producing composition for promoting secretion of GLP-1, use of GPR84 agonist for producing therapeutic agent for disease, GLP-1 secretion promotion agent, and composition for oral ingestion
<a href="#">WO2022197703</a>	MEMORIAL SLOAN KETTERING CANCER CENTER [US]; UNIV MICHIGAN STATE [US]; MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES [US]; SLOAN KETTERING INST CANCER RES [US]	Wound healing enhancement with anti-ceramide antibodies
<a href="#">WO2022197854</a>	WISCONSIN ALUMNI RES FOUND [US]	Insulin gene therapy to treat diabetes
<a href="#">WO2022187182</a>	UNIV PENNSYLVANIA [US]	Targeting T regulatory cells to islet cells to stall or reverse type 1 diabetes
<a href="#">WO2022186652</a>	UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV [KR]; UNIV KOREA RES & BUS FOUND [KR]	Method and kit for diagnosing diabetes by using tears
<a href="#">WO2022250556</a>	CELON PHARMA SA [PL]; UNIV WROCLAWSKI [PL]	Human fibroblast growth factor 1 (FGF-1) muteins, their dimers and uses
<a href="#">WO2022240916</a>	UNIV COLORADO REGENTS [US]	Engineered HLA alleles for treating autoimmunity
<a href="#">WO2022234511</a>	PROBIONOVA SA [CH]	Compositions based on bacterial strains for the treatment of alterations in carbohydrate metabolism
<a href="#">WO2022240783</a>	REGENERON PHARMA [US]	Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022248588</a>	CAELUS PHARMACEUTICALS B V [NL]	Insulin-sensitizing agent and butyrate-producing bacterium
<a href="#">WO2022226197</a>	US HEALTH [US]	Human insulin c-alpha-peptides and methods of use
<a href="#">WO2022204377</a>	SALK INST FOR BIOLOGICAL STUDI [US]	Novel chemical combinations and methods of use thereof, towards differentiation of human progenitor cells into functional $\beta$ cells
<a href="#">WO2022189344</a>	UNIV GENT [BE]	Treatment of eye diseases with fructosyl-amino acid oxidase

# Sistema Nervioso

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022262624</a>	UNIV XIAMEN [CN]	Pharmaceutical use of $\beta$ 2-microglobulin or inhibitor thereof
<a href="#">WO2022256557</a>	DYNO THERAPEUTICS INC [US]	Capsid variants and methods of using the same
<a href="#">WO2022256257</a>	AVOTRES INC [US]	A therapeutic preparation and methods for treating autoimmune diseases
<a href="#">WO2022256694</a>	UNIV SOUTHERN CALIFORNIA [US]	Novel therapeutic peptides for neurodegeneration
<a href="#">WO2022256331</a>	SCHEPENS EYE RES INST [US]	Methods for treating neurodegeneration targeting IGF1/IGF1R
<a href="#">WO2022251254</a>	UNIV JOHNS HOPKINS [US]; UNIV SOUTHERN CALIFORNIA [US]	Pharmacological intervention of the arachidonic acid pathway to cure amyotrophic lateral sclerosis
<a href="#">WO2022246433</a>	UNIV TENNESSEE RES FOUND [US]; ATTRALUS INC [US]	Antibody-peptide fusion proteins for treating amyloid disorders
<a href="#">WO2022241566</a>	ALPHA COGNITION INC [CA]	Granulin/epithelin modules and combinations thereof to treat neurodegenerative disease
<a href="#">WO2022239820</a>	FOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE [JP]; NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION [JP]; MEIJI SEIKA PHARMA CO LTD [JP]	Anti-human PD-1 agonist antibody for treating or preventing inflammatory diseases, and pharmaceutical composition containing same
<a href="#">WO2022239765</a>	O FORCE CO LTD [JP]	Amyloid- $\beta$ aggregation inhibitor, pharmaceutical composition for amyloid- $\beta$ aggregation diseases, and use application of same
<a href="#">WO2022240649</a>	ALKAHEST INC [US]	Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators
<a href="#">WO2022240251</a>	IUCF HYU [KR]	Biomarker for prognosis prediction of neurodegenerative diseases, comprising miRNAs, and use thereof
<a href="#">WO202221404</a>	CAPSIDA INC [US]	Adeno-associated virus compositions having increased brain enrichment

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022220236</a>	UNIV KYOTO [JP]	Information processing method, information processing device, and program
<a href="#">WO2022217141</a>	UNIV ARIZONA [US]	Development of aptamers for neutralizing antibodies in demyelinating diseases
<a href="#">WO2022216145</a>	UNIV GACHON IND ACAD COOP FOUND [KR]; KOREA VETERANS HEALTH SERVICE [KR]	Biomarker for neurodegenerative diseases comprising glycotoxin, specific protein bound to glycotoxin, or glycotoxin-specific protein complex
<a href="#">WO2022215066</a>	ITAYANDBIOND LTD [IL]	Small activating RNA increasing shank expression and method of treating intellectual disabilities and associated comorbidities associated with shank haploinsufficiency
<a href="#">ES2924776</a>	UNIV CASTILLA LA MANCHA [ES]	Métodos para el diagnóstico y pronóstico de la enfermedad de Alzheimer
<a href="#">WO2022212756</a>	UNIV WASHINGTON [US]	CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
<a href="#">WO2022211454</a>	HELIXMITH CO LTD [KR]	Pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease
<a href="#">WO2022206819</a>	UNIV NANJING [CN]	RNA delivery system for treatment of Huntington's disease
<a href="#">WO2022212208</a>	UNIV MASSACHUSETTS [US]	Oligonucleotides for SYNGR-3 modulation
<a href="#">WO2022206767</a>	UNIV SCIENCE & TECHNOLOGY CHINA [CN]	Use of GPR34 inhibitor in preparation of drug for treating demyelination-related diseases
<a href="#">WO2022204293</a>	UNIV ARIZONA STATE [US]	Selective targeting of oligomeric $\beta$ -amyloid
<a href="#">WO2022201167</a>	UNIV RAMOT [IL]	Use of ADFN polypeptides in therapy
<a href="#">WO2022195553</a>	UNIV BRITISH COLUMBIA [CA]; INCISIVE GENETICS INC [CA]	Guide RNAs and compositions for editing huntingtin gene, and methods related thereto
<a href="#">WO2022198072</a>	UNIV BROWN [US]	Characterizing the binding interactions between MuSK and BMP receptors
<a href="#">WO2022197974</a>	UNIV FLORIDA [US]	Chimeric phagocytic receptors for treatment of neurodegenerative disorders
<a href="#">WO2022192019</a>	CHILDRENS MEDICAL CT CORP [US]	Methods for diagnosis and treatment of Alzheimer's disease



Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022251597</a>	VERGE ANALYTICS INC [US]	Methods of treating neurological disorders with modulators of ribosomal protein S6 kinase alpha-1 (RSK1) and ribosomal protein S6 kinase alpha-3 (RSK2)
<a href="#">WO2022235911</a>	FUJIFILM CELLULAR DYNAMICS INC [US]	Methods and compositions for iPSC-derived microglia
<a href="#">WO2022258712</a>	AMRIF BV [NL]	Alkaline phosphatase for use in the treatment of a neurodegenerative disorder
<a href="#">WO2022258555</a>	HOFFMANN LA ROCHE [CH]; HOFFMANN LA ROCHE [US]	Oligonucleotide progranulin agonists
<a href="#">WO2022229705</a>	GRIFOLS WORLDWIDE OPERATIONS LTD [IE]	Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment
<a href="#">WO2022241082</a>	GENENTECH INC [US]	Agonists of TREM2
<a href="#">WO2022226375</a>	LOCANABIO INC [US]	Tissue-targeted modified AAV capsids and methods of use thereof
<a href="#">WO2022233764</a>	UCB BIOPHARMA SRL [BE]	Antibodies
<a href="#">WO2022226197</a>	US HEALTH [US]	Human insulin C-alpha-peptides and methods of use
<a href="#">WO2022221278</a>	LOCANABIO INC [US]	Compositions and methods comprising hybrid promoters
<a href="#">WO2022212231</a>	ALNYLAM PHARMACEUTICALS INC [US]	Huntingtin (HTT) iRNA agent compositions and methods of use thereof
<a href="#">WO2022219353</a>	CAMBRIDGE ENTPR LTD [GB]; UCL BUSINESS LTD [GB]	Somatic expansion inhibitors
<a href="#">WO2022219200</a>	UCL BUSINESS LTD [GB]	CasRx/Cas13d systems targeting C9orf72
<a href="#">WO2022212459</a>	BIOGEN MA INC [US]	Treatment of amyotrophic lateral sclerosis
<a href="#">WO2022214494</a>	CONSEJO SUPERIOR INVESTIGACION [ES]; UNIV AUTONOMA DE MADRID UAM [ES]	A new non-aggregative splicing isoform of human tau is decreased in Alzheimer's disease
<a href="#">WO2022214717</a>	FUNDACIO ACE INST CATALA DE NEUROCIENCIAS APLICADES [ES]; UNIV KOELN [DE]	Cerebrospinal fluid biomarker for Alzheimer's disease
<a href="#">WO2022200355</a>	CELLTREND GMBH [DE]	Diagnosis of Alzheimer's disease by detecting auto-antibodies against Y-box binding protein-1 (Yb-1)
<a href="#">WO2022211893</a>	TRAILHEAD BIOSYSTEMS INC [US]	Methods and compositions for generating oligodendrocyte progenitor cells

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022218499</a>	ALPHABETA AB [SE]	Facilitated passage over the blood-brain barrier by co-administration of Bri2 BRICHOS domain and lipid microbubbles and/or nanodroplets
<a href="#">WO2022199804</a>	VIB VZW [BE]; KATHOLIEKE UNIV LEUVEN K U LEUVEN R&D [BE]	NEK6 inhibition to treat ALS and FTD
<a href="#">WO2022248615</a>	INST NAT SANTE RECH MED [FR]; UNIV MONTPELLIER [FR]; UNIV DE PERPIGNAN VIA DOMITIA [FR]	Hexokinase-derived peptides and therapeutical uses thereof
<a href="#">WO2022226127</a>	ALEXION PHARMA INC [US]	Compositions and methods for inhibiting complement component 3 expression
<a href="#">WO2022211544</a>	IUCF HYU [KR]	Regulatory T cell-derived peptide and composition including same for prevention or treatment of autoimmune disease
<a href="#">WO2022195963</a>	UNIV HOKKAIDO NAT UNIV CORP [JP]	Microglial M1 polarization inhibitor and pharmaceutical composition
<a href="#">WO2022198073</a>	UNIV CALIFORNIA [US]	Compositions and methods for targeting inflammatory or activated cells and treating or ameliorating inflammatory conditions and pain
<a href="#">WO2022246078</a>	LILLY CO ELI [US]	Compounds and methods targeting epiregulin

# Sistema Inmune

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022255848</a>	DOKNIP BIOPHARM CO [KR]	Novel peptide derived from <i>Agkistrodon piscivorus piscivorus</i> or <i>Naja melanoleuca</i> , and composition for treatment of Behcet's disease or rheumatoid arthritis comprising same
<a href="#">WO2022255781</a>	CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]; SEOUL NAT UNIV R&DB FOUNDATION [KR]	Biomarker for disease activity assessment, diagnosis, and onset prediction of rheumatoid arthritis
<a href="#">WO2022255782</a>	CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]; SEOUL NAT UNIV R&DB FOUNDATION [KR]	Biomarkers for predicting response to treatment of rheumatoid arthritis
<a href="#">WO2022255929</a>	STIFTELSEN VECTIS [SE]	Novel peptide mimics and their use
<a href="#">WO2022251164</a>	SYNTHETIC BIOLOGICS INC [US]	Alkaline phosphatase-based treatments of celiac disease
<a href="#">WO2022246565</a>	UNIV LAVAL [CA]	Methods and kits for diagnosing systemic autoimmune rheumatic diseases
<a href="#">WO2022240997</a>	UNIV MICHIGAN REGENTS [US]	Regulating T cell immune response through IGF-1 receptor (IGF-1R)
<a href="#">WO2022239820</a>	FOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE [JP]; NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION [JP]; MEIJI SEIKA PHARMA CO LTD [JP]	Anti-human PD-1 agonist antibody for treating or preventing inflammatory diseases, and pharmaceutical composition containing same
<a href="#">WO2022239986</a>	IMMUNOLOGICAL DESIGNING LAB INC [KR]	Chimeric antigen receptor comprising extracellular domain of BAFF and use thereof
<a href="#">WO2022237835</a>	HSIN SHAOCHI [CN]	Method for treatment of psoriasis
<a href="#">WO2022236365</a>	MICROBA IP PTY LTD [AU]	Compositions and methods for treating disease
<a href="#">WO2022235482</a>	UNIV RUTGERS [US]	Immunotherapy for inflammatory bowel disease and/or cancer

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022234976</a>	IMMUNOLOGICAL DESIGNING LAB INC [KR]	Transformed antigen-specific professional antigen-presenting cell containing chimeric antigen receptor (CAR) and use thereof
<a href="#">WO2022231083</a>	CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]	Composition, for preventing or treating autoimmune disease, comprising mitochondria as active ingredient
<a href="#">WO2022226037</a>	CUE BIOPHARMA INC [US]	Antigen presenting polypeptide complexes bearing TGF-beta and methods of use thereof
<a href="#">WO2022226127</a>	ALEXION PHARMA INC [US]	Compositions and methods for inhibiting complement component 3 expression
<a href="#">WO2022226451</a>	UNIV OF LOUISVILLE [US]; JAGIELLONIAN UNIV [PL]	Recombinant miropin
<a href="#">WO2022216615</a>	RHODE ISLAND HOSPITAL [US]	Compositions and methods for the prevention or treatment of rheumatoid arthritis
<a href="#">WO2022212354</a>	ALLEGRO PHARMACEUTICALS LLC [US]	Inhibition of tumor necrosis factor, pro-inflammatory cytokines and other inflammatory response mediators
<a href="#">WO2022199603</a>	NANJING GENSCRIPT BIOTECH CO LTD [CN]	Antibody fusion proteins and uses thereof
<a href="#">WO2022202099</a>	UNIV OSAKA [JP]	Method for testing for inflammatory bowel disease
<a href="#">WO2022192955</a>	UNIV JAMES COOK [AU]	Proteins and uses thereof
<a href="#">WO2022197610</a>	JN BIOSCIENCES LLC [US]	Bifunctional molecules for treatment of immune disorders
<a href="#">WO2022197968</a>	SCIPHER MEDICINE CORP [US]	Methods of classifying and treating patients
<a href="#">WO2022192445</a>	SURROZEN OPERATING INC [US]	Modulation of WNT signaling in gastrointestinal disorders
<a href="#">WO2022191341</a>	EXOSTEMTECH CO LTD [KR]	Pharmaceutical composition comprising stem cell-derived exosome for palliating or treating arthritis
<a href="#">WO2022192236</a>	SHATTUCK LABS INC [US]	Chimeric proteins in autoimmunity
<a href="#">WO2022174067</a>	UNIV LELAND STANFORD JUNIOR [US]	Methods relating to anti-IL-1 therapy and anti-IL-6 therapy and hypersensitivity
<a href="#">WO2022261341</a>	REGENERON PHARMA [US]	Treatment of psoriasis with Interferon Induced Helicase C Domain 1 (IFIH1) inhibitors

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022261455</a>	FZATA INC [US]	Genetically-modified <i>Saccharomyces</i> yeast strains as preventative and therapeutic agents
<a href="#">WO2022251623</a>	LILLY CO ELI [US]	Anti-IL-23p19 antibody regulation of genes involved in ulcerative colitis
<a href="#">WO2022268939</a>	ADVANCECOR GMBH [DE]	Peptides for the treatment of chronically active autoimmune inflammation
<a href="#">WO2022258979</a>	QUELL THERAPEUTICS LTD [GB]	Chimeric receptor
<a href="#">WO2022246225</a>	VIELA BIO INC [US]	CD40L antagonist and uses thereof in the treatment of lupus nephritis
<a href="#">WO2022246225</a>	VIELA BIO INC [US]	CD40L antagonist and uses thereof in the treatment of lupus nephritis
<a href="#">WO2022240916</a>	UNIV COLORADO REGENTS [US]	Engineered HLA alleles for treating autoimmunity
<a href="#">WO2022240915</a>	UNIV COLORADO REGENTS [US]	Engineered HLA alleles for treating autoimmunity
<a href="#">WO2022243937</a>	JANSSEN BIOTECH INC [US]	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
<a href="#">WO2022253910</a>	INST NAT SANTE RECH MED [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV TOULOUSE III - PAUL SABATIER [FR]	A new method to treat an inflammatory skin disease
<a href="#">WO2022232253</a>	CEDARS SINAI MEDICAL CENTER [US]	Patient selection methods and kits for therapies targeting TL1A
<a href="#">WO2022234440</a>	NOVARTIS AG [CH]	Treatment for lupus nephritis using anti-BAFFR antibodies
<a href="#">WO2022234439</a>	NOVARTIS AG [CH]	Treatment for systemic lupus erythematosus using anti-BAFFR antibodies
<a href="#">WO2022221409</a>	VILLARIS THERAPEUTICS INC [US]	Anti-CD122 antibodies and uses thereof
<a href="#">WO2022208341</a>	SYNBALANCE SRL [IT]	Probiotic compositions useful in the prevention and/or treatment of gastrointestinal disorders
<a href="#">WO2022223770</a>	ASTRAZENECA AB [SE]	Treatment of cutaneous lupus erythematosus
<a href="#">WO2022195237</a>	UNIV TOULOUSE 3 PAUL SABATIER [FR]; INST NAT SANTE RECH MED [FR]; CT HOSPITALIER UNIVERSITAIRE TOULOUSE [FR]; CT HOSPITALIER UNIVERSITAIRE MONTPELLIER [FR]; UNIV MONTPELLIER [FR]; ARTHRITIS RECH & DEVELOPPEMENT [FR]	Hybrid molecule comprising an antibody Fc fragment and at least one fibrin-derived citrullinated peptide, and uses thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022195239</a>	UNIV TOULOUSE 3 PAUL SABATIER [FR]; INST NAT SANTE RECH MED [FR]; CT HOSPITALIER UNIVERSITAIRE TOULOUSE [FR]; CT HOSPITALIER UNIVERSITAIRE MONTPELLIER [FR]; UNIV MONTPELLIER [FR]; ARTHRITIS RECH & DEVELOPPEMENT [FR]	Immune cell which has an Fc receptor on its surface and to which is grafted a hybrid molecule comprising an antibody Fc fragment and at least one fibrin-derived citrulline peptide, and uses thereof
<a href="#">WO2022197699</a>	LILLY CO ELI [US]	Human TSPAN33 antibodies
<a href="#">WO2022192647</a>	GENENTECH INC [US]	Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
<a href="#">WO2022192419</a>	MASSACHUSETTS INST TECHNOLOGY [US]; SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST [US]; CHILDRENS MEDICAL CT CORP [US]	Methods of predicting response to anti-TNF blockade in inflammatory bowel disease
<a href="#">WO2022207921</a>	UNIV WUERZBURG J MAXIMILIANS [DE]	Novel TNFR2 binding molecules
<a href="#">WO2022207685</a>	HOFFMANN LA ROCHE [CH]; ROCHE DIAGNOSTICS GMBH [DE]; ROCHE DIAGNOSTICS OPERATIONS INC [US]	PSP94 as blood biomarker for the non-invasive diagnosis of endometriosis
<a href="#">WO2022207628</a>	HOFFMANN LA ROCHE [CH]; ROCHE DIAGNOSTICS GMBH [DE]; ROCHE DIAGNOSTICS OPERATIONS INC [US]	SCF as blood biomarker for the non-invasive diagnosis of endometriosis
<a href="#">WO2022207721</a>	DUPONT NUTRITION BIOSCI APS [DK]	Compositions and methods for treating and preventing gastrointestinal inflammation
<a href="#">WO2022195115</a>	ELIGO BIOSCIENCE [FR]	Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating subacute cutaneous lupus erythematosus
<a href="#">WO2022195028</a>	MEDIMMUNE LTD [GB]	Therapeutic binding molecule that binds to CCR9
<a href="#">WO2022190036</a>	JANSSEN BIOTECH INC [US]	Methods for predicting treatment response in ulcerative colitis
<a href="#">WO2022220275</a>	CHUGAI PHARMACEUTICAL CO LTD [JP]	Anti-C1s antibody
<a href="#">WO2022221478</a>	TSCAN THERAPEUTICS INC [US]; NAYAR RIBHU [US]; MACBEATH GAVIN [US]; JANGALWE SONAL [US]; JUREWICZ MOLLIE M [US]; BASINSKI ANDREW S [US]; XU QIKAI [US]; BOUDOT ANTOINE J [US]; KULA TOMASZ [US]	Binding proteins recognizing HA-2 antigen and uses thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<a href="#">WO2022191182</a>	JUNTENDO EDUCATIONAL FOUND [JP]; KYOWA KIRIN CO LTD [JP]; KYOWA HAKKO BIO CO LTD [JP]	Composition and ameliorating agent having inflammation reducing effect
<a href="#">WO2022189567</a>	DEUTSCHES KREBSFORSCH [DE]	Immune enhancers
<a href="#">WO2022198073</a>	UNIV CALIFORNIA [US]	Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain
<a href="#">WO2022212393</a>	UNIV CALIFORNIA [US]	Transplanted cell protection via modified Fc receptors
<a href="#">WO2022234511</a>	PROBIONOVA SA [CH]	Compositions based on bacterial strains for the treatment of alterations in carbohydrate metabolism
<a href="#">WO2022219168</a>	UNIV COLLEGE CORK NATIONAL UNIV OF IRELAND CORK [IE]	PSG1 for use in the treatment of osteoarthritis
<a href="#">WO2022183014</a>	SIGNALCHEM PLANTECH CORP [CA]	Methods of high production of polyphenols from red lettuces and uses thereof

# Noticias

## NUEVA DIRECTORA DE LA OEPM

El pasado 4 de octubre el Consejo de Ministros nombró a Aida Fernández González Directora de la [Oficina Española de Patentes y Marcas, O.A. \(OEPM\)](#).

La nueva directora es licenciada en Periodismo por la Facultad de Ciencias de la Información de la Universidad Complutense de Madrid y posteriormente realizó el Máster de Periodismo del Diario ABC, colaborando en este medio de comunicación

En el año 2010 ingresó en el Cuerpo Superior de Administradores Civiles del Estado. En la Administración General del Estado ha prestado servicios como Jefa de Gabinete de la Subsecretaría del Ministerio de Economía y Empresa, Asesora Parlamentaria del Gabinete de la Vicepresidenta del Gobierno y Ministra de la Presidencia y del Ministro de Economía y Competitividad, así como Consejera Técnica del Gabinete de la Subsecretaría de Fomento. Desde el año 2018 ha sido Jefa de Gabinete de la Subsecretaría de Asuntos Económicos y Transformación Digital.

¡Le deseamos el mayor de los éxitos en esta nueva etapa!

### [Más información](#)





## JORNADA DE ESTUDIO Y ACTUALIZACIÓN EN MATERIA DE PATENTES: "LUNES DE PATENTES"

El pasado 28 de noviembre tuvo lugar de forma presencial en la OEPM una sesión más de *Los lunes de Patentes*.

Desde el año 2001 la [Oficina Española de Patentes y Marcas, O.A. \(OEPM\)](#) y el [Centro de Patentes de la Universidad de Barcelona \(UB\)](#), organizan estas jornadas, dos de ellas en la OEPM y dos en la UB.

Se trata de un foro de aprendizaje y discusión en materia de patentes, cuyo objetivo fundamental es mantener al día a los profesionales de patentes de todos los ámbitos laborales (empresas, agencias de propiedad industrial, oficinas de patentes, bufetes, enseñanza), y de todas las especialidades (técnica, jurídica, gestión, etc...).

Los temas que se trataron a lo largo de la jornada fueron la actualización normativa, con la modificación de la Ley de Patentes, la prueba pericial técnica, y la atribución a lo mercantil de la competencia para conocer de los recursos contra las resoluciones de la OEPM.

Esta jornada tiene carácter pro bono, siendo de tipo presencial y la asistencia gratuita.

La documentación está disponible en la página web del centro de patentes de la Universidad de Barcelona <http://www.ub.edu/centrepatents/es/cursos/dilluns.html>

### Más información



## CAMPAÑA PUBLICIDAD: LA VERDAD DE LAS FALSIFICACIONES

El Black Friday es una de las fechas significativas del mes de noviembre, por las numerosas compras que se realizan en todos los ámbitos. En la [Oficina Española de Patentes y Marcas, O.A. \(OEPM\)](#) somos conscientes de ello, y por eso año tras año, lanzamos en estos días una campaña para estimular la compra de productos originales.

La Ministra de Industria, Comercio y Turismo, Reyes Maroto presidió el acto de presentación de la campaña publicitaria junto con el Subsecretario y Presidente de la OEPM, Pablo Garde, y la Directora de la OEPM, Aida Fernández. Asistieron asimismo al acto de presentación representantes del sector público relacionados con la lucha frente al fenómeno de las falsificaciones, como las Fuerzas y Cuerpos de Seguridad del Estado, y representantes del sector privado como asociaciones de consumidores, o de marcas, entre otros.

La campaña de este año, con el lema **LA VERDAD DE LAS FALSIFICACIONES** pretende informar y concienciar de que el consumo de estos productos falsificados hace que se cierren empleos, se ponga en riesgo la salud, o se contribuya a la contaminación global.

Esta campaña se ha querido humanizar utilizando la pareidolia, haciendo que los productos falsificados cobren vida y confiesen el daño que han infligido a las personas bajo un foco de luz similar al de un interrogatorio policial.

El formato visual que se ha utilizado es moderno y con colores vivos. Mediante esta creatividad se ha conseguido realizar una concienciación más profunda en el público objetivo.

### [Más información](#)



## XXI REUNIÓN ANUAL CENTROS REGIONALES DE INFORMACIÓN EN MATERIA DE PROPIEDAD INDUSTRIAL

Los días 7 y 8 de noviembre tuvo lugar en Valencia la XXI reunión anual de [Centros Regionales de Información en materia de Propiedad Industrial \(CCRR\)](#).

Esta reunión anual sirve de punto de encuentro entre la [OEPM](#) y los centros regionales, permitiendo que las relaciones entre todas las instituciones sean estrechas y fluidas.

La jornada coincidió con el [V Congreso de Industria Conectada](#), y además de poder asistir al congreso, los participantes por parte de los CCRR tuvieron la oportunidad de asistir a ponencias y encuentros específicos para ellos.

Las sesiones, presentadas por personal de la OEPM, trataron sobre las novedades legislativas de patentes y diseños industriales y asimismo sobre la nulidad y la caducidad de las marcas, despertando estos temas gran interés entre los participantes.

La última parte estuvo dedicada a la casuística de cada uno de los centros, durante la cual se pudieron compartir experiencias y su proyección de futuro.

Esta reunión permitió estrechar los lazos existentes entre la OEPM y los Centros Regionales, así como reforzar las sinergias y ámbitos de colaboración entre las diferentes entidades.